A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of JNJ-54861911 on the QT/QTc intervals
in healthy participants, when administered at therapeutic (50 milligram [mg] once-daily) and
supratherapeutic (150 mg once-daily) doses for 7 days.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination